infigratinib
bridgebio pharmaceutical
['biomarker', 'proof-302']
thx for opportunity to lead genomic analysis on #proof-302 w/ critical implications for designing fgfr3 biomarker-driven trials. what a great discussion by in this important session! #asco23 
GU oncologist, clinical trialist, Director GU Oncology @CleclinicMD Tweets my own, RT/Likes not active endorsement.